Therapeutic Response

HER2-negative and PR positive status confers therapeutic sensitivity to Abemaciclib in patients with Invasive Breast Carcinoma.

Statements

Source and description
Verzenio (abemaciclib) [product monograph]. HC. Health Canada approved abemaciclib in combination with an aromatase inhibitor, in combination with fulvestrant, or as a single agent for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy, in women with disease progression following endocrine therapy, or in women with disease progression following endocrine therapy and at least two prior chemotherapy regimens.
Verzenio (abemaciclib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.